Cancer Clinical Trials
This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.
High Risk Breast Cancer
Trial Name: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.
Protocol ID: NSABP B-47
Pregnancy or lactation at the time of study entry.
Enrollment: • • About 3, 260 women from different cancer treatment centers will take part in this study.
Taking part in this study may or may not make your health better. While doctors hope that adding trastuzumab to chemotherapy will be more useful in treating HER2-low breast cancer compared to the usual treatment, there is no proof of this yet. We do know that the information from this study will help doctors learn more about trastuzumab given with chemotherapy as a treatment for HER2-low breast cancer. This information could help future breast cancer patients.
These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.
Created: Jun 3, 2011
Updated: May 21, 2014